307 related articles for article (PubMed ID: 9806109)
1. Abciximab. An updated review of its use in ischaemic heart disease.
Foster RH; Wiseman LR
Drugs; 1998 Oct; 56(4):629-65. PubMed ID: 9806109
[TBL] [Abstract][Full Text] [Related]
2. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Ibbotson T; McGavin JK; Goa KL
Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
[TBL] [Abstract][Full Text] [Related]
3. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
Dunn CJ; Foster RH
Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
[TBL] [Abstract][Full Text] [Related]
6. A risk-benefit assessment of abciximab in angioplasty.
Kleiman NS
Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schühlen H; Schömig A; Berger PB; Mehilli J; Neumann FJ;
EuroIntervention; 2013 Aug; 9(4):430-6. PubMed ID: 23455033
[TBL] [Abstract][Full Text] [Related]
8. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Simoons ML;
Lancet; 2001 Jun; 357(9272):1915-24. PubMed ID: 11425411
[TBL] [Abstract][Full Text] [Related]
10. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.
Faulds D; Sorkin EM
Drugs; 1994 Oct; 48(4):583-98. PubMed ID: 7528131
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
12. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
13. [The use of Abciximab in patients with acute myocardial infarction undergoing direct percutaneous coronary revascularization].
Silveira C; Ferreira RC; Quininha J; Ferreira Mde L; Gonçalves JM; Ramos JS; Figueiredo L; Antunes AM
Rev Port Cardiol; 1999 Sep; 18(9):815-9. PubMed ID: 10536471
[TBL] [Abstract][Full Text] [Related]
14. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of abciximab during routine medical practice.
Reed SO; Mullins CD; Magder LS
Pharmacoeconomics; 2000 Sep; 18(3):265-74. PubMed ID: 11147393
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with abciximab during coronary revascularisation: an overview.
Guetta V; Lincoff AM
BioDrugs; 1998 Jul; 10(1):27-39. PubMed ID: 18020584
[TBL] [Abstract][Full Text] [Related]
18. The use of abciximab in coronary angioplasty--an Asian centre's experience.
Tan HC; Lim YT; Lim TT; Cheng A; Chia BL
Singapore Med J; 2000 Feb; 41(2):69-73. PubMed ID: 11063206
[TBL] [Abstract][Full Text] [Related]
19. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]